1-9 of 9
Gail Larkins
Close
Sort by
Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3122.
https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122
Published: 2017
Journal Articles

Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)

Sikander Ailawadhi, Gail Larkins, RN, MBA, Weiyuan Chung, Shankar Srinivasan, PhD, Amit Agarwal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3428.
https://doi.org/10.1182/blood.V130.Suppl_1.3428.3428
Published: 2017
Journal Articles

Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM ® Disease Registry

Jatin J. Shah, MD, Rafat Abonour, MD, Mohit Narang, Jayesh Mehta, Howard R. Terebelo, Cristina J Gasparetto, Kathleen Toomey, James W Hardin, Shankar Srinivasan, Gail Larkins, Yasir Nagarwala, Robert M. Rifkin
Journal: Blood
Blood (2015) 126 (23): 4229.
https://doi.org/10.1182/blood.V126.23.4229.4229
Published: 2015
Journal Articles

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Clinical Trials & Observations
Paul G. Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Jacob Laubach, Daniel Sullivan, Melissa Alsina, Robert Schlossman, Irene M. Ghobrial, Deborah Doss, Nora Loughney, Laura McBride, Elizabeth Bilotti, Palka Anand, Lisa Nardelli, Sandra Wear, Gail Larkins, Min Chen, Mohamad H. Zaki, Christian Jacques, Kenneth C. Anderson
Journal: Blood
Blood (2013) 121 (11): 1961–1967.
https://doi.org/10.1182/blood-2012-08-450742
Published: 2013
Journal Articles

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)

Paul G. Richardson, MD, Andrzej Jakubowiak, MD, PhD, Nizar J. Bahlis, MD, David S. Siegel, MD, PhD, Christine I. Chen, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2012) 120 (21): 4053.
https://doi.org/10.1182/blood.V120.21.4053.4053
Published: 2012
Journal Articles

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

Ravi Vij, MD, Craig C. Hofmeister, MD, Paul G. Richardson, MD, Sundar Jagannath, MD, David S. Siegel, MD, PhD, Rachid Baz, MD, Min Chen, PhD, Mohamed Zaki, MD, Gail Larkins, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2012) 120 (21): 4070.
https://doi.org/10.1182/blood.V120.21.4070.4070
Published: 2012
Journal Articles

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Paul G. Richardson, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Craig C. Hofmeister, MD, Sundar Jagannath, MD, Christine Chen, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Nizar J Bahlis, MD, Rachid Baz, MD, Gail Larkins, RN, Min Chen, PhD, Mohamed Zaki, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 634.
https://doi.org/10.1182/blood.V118.21.634.634
Published: 2011
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 864.
https://doi.org/10.1182/blood.V116.21.864.864
Published: 2010
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Laura McBride, Deborah Doss, Gail Larkins, Christian Jacques, Arlene Donaldson, Kenneth C. Anderson
Journal: Blood
Blood (2009) 114 (22): 301.
https://doi.org/10.1182/blood.V114.22.301.301
Published: 2009